THE HONG KONG JOCKEY CLUB CELEBRATES THE FINAL EIGHT WITH "EIGHT TO GLORY, PRESENTED BY LENOVO"

THE HONG KONG JOCKEY CLUB CELEBRATES THE FINAL EIGHT WITH "EIGHT TO GLORY, PRESENTED BY LENOVO"

LINK TO REAL TIME IMAGES AND VIDEOS HERE. HONG KONG, July 9, 2026 /PRNewswire/ -- On Wednesday, July 8 at Happy Valley, The Hong Kong Jockey Club (the Club) presented a special race to capture a singular cultural moment: where the world's love of...

ICAC Commissioner attends first IAACA European regional anti-corruption conference in Hungary

ICAC Commissioner attends first IAACA European regional anti-corruption conference in Hungary

BUDAPEST, Hungary, July 2, 2026 /PRNewswire/ -- ICAC Commissioner, Mr Woo Ying-ming, in his capacity of President of the International Association of Anti-Corruption Authorities (IAACA), successfully concluded the first European regional...

Everest Medicines and Hainan Herui have entered into a commercialization collaboration relating to Hainan Herui's budesonide enteric capsules

Everest Medicines and Hainan Herui have entered into a commercialization collaboration relating to Hainan Herui's budesonide enteric capsules

SHANGHAI, June 24, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today...

Abbisko Therapeutics Deepens R&D Collaboration with Lilly

Abbisko Therapeutics Deepens R&D Collaboration with Lilly

SHANGHAI, June 24, 2026 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced that it has entered into a strategic research collaboration and license agreement with Eli Lilly and...

Lynk Pharmaceuticals' Partner Formation Bio Doses First Participant in Phase 1 Trial of BLKR201 (originally designated as LNK01006), a CNS-Penetrant TYK2 Inhibitor

Lynk Pharmaceuticals' Partner Formation Bio Doses First Participant in Phase 1 Trial of BLKR201 (originally designated as LNK01006), a CNS-Penetrant TYK2 Inhibitor

HANGZHOU, China, SHANGHAI and BOSTON, June 10, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on autoimmune and inflammatory diseases, today announced a...

Nature's Miracle Holding Inc Reports Q1 2026 Net Income of $2.8 Million with Fully Diluted EPS of $0.01 and Strategic Expansion into U.S. Advanced Contract Manufacturing for Drone and AI Data Center

Nature's Miracle Holding Inc Reports Q1 2026 Net Income of $2.8 Million with Fully Diluted EPS of $0.01 and Strategic Expansion into U.S. Advanced Contract Manufacturing for Drone and AI Data Center

ONTARIO, Calif., May 28, 2026 /PRNewswire/ -- Nature's Miracle Holding Inc. ("Nature's Miracle" or the "Company") (OTCID: NMHI), a leader in controlled environment agriculture, vertical farming and infrastructure solutions, today announced financial...

U Power Hydro Data Joint Venture Secures Thailand Data Center Energy Project 3MW Pilot for Planned 100MW Deployment

U Power Hydro Data Joint Venture Secures Thailand Data Center Energy Project 3MW Pilot for Planned 100MW Deployment

BANGKOK, Thailand, May 27, 2026 /PRNewswire/ -- U Power Limited (Nasdaq: UCAR) ("U Power" or the "Company"), a provider of AI-integrated solutions for next-generation energy grids and intelligent transportation systems, building on its proprietary...

TCL Electronics (01070.HK) Maintains Strong Growth in Q1 2026

TCL Electronics (01070.HK) Maintains Strong Growth in Q1 2026

Adjusted Profit Attributable to Owners of the Parent Surge s by 140.0% YoY to HK$384 Million Officially Partner ed with Sony to Expand t he Global Home Entertainment Industry Results Highlights Leveraging the dual-drive strategy of "Globalisation"...

High-Trend International Group Announces Pricing of $15 Million Registered Direct Offering with Global Institutional Investors

High-Trend International Group Announces Pricing of $15 Million Registered Direct Offering with Global Institutional Investors

NEW YORK, May 13, 2026 /PRNewswire/ -- High-Trend International Group (NASDAQ: HTCO) ("HTCO" or the "Company"), a global ocean transportation company, today announced that it has entered into securities purchase agreements with global institutional...

The sNDA for Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First‑Line Treatment for PD-L1-positive NSCLC Accepted for Review by NMPA

The sNDA for Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First‑Line Treatment for PD-L1-positive NSCLC Accepted for Review by NMPA

CHENGDU, China, May 8, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company") announced that the sNDA (the "Application") for the Company's TROP2 ADC sacituzumab tirumotecan (sac-TMT, also known as...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • menu
    menu